Metabolic conditions

Latest articles

Previous research has shown the aging process and frailty may be associated with a perturbed gut microbiome in elderly people. Indeed, gut microbes could be a major driver of age-associated inflammation in mice, and specific microbial signatures of healthy aging have been previously reported in long-lived individuals. However, it is still unknown whether targeting gut microbes can be effective in…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

Previous research has shown the aging process and frailty may be associated with a perturbed gut microbiome in elderly people. Indeed, gut microbes could be a major driver of age-associated inflammation in mice, and specific microbial signatures of healthy aging have been previously reported in long-lived individuals. However, it is still unknown whether targeting gut microbes can be effective in…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

It is well-known that medications could affect the microbiome and therefore host-microbiota interactions are considered a confounding factor that can contribute to therapeutic and side effects of drug treatments. Previous research has shown that gut microbiota may partially mediate both therapeutic and adverse effects of metformin, which is the most prescribed drug for the treatment of individuals with type 2…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

It is well-known that medications could affect the microbiome and therefore host-microbiota interactions are considered a confounding factor that can contribute to therapeutic and side effects of drug treatments. Previous research has shown that gut microbiota may partially mediate both therapeutic and adverse effects of metformin, which is the most prescribed drug for the treatment of individuals with type 2…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

For those seeking the latest science on gut health and its applications to clinical practice, Paris was the place to be on March 11th and 12th, 2017. At the 6th GMFH World Summit, over 400 professionals from all over the world met to review the past decade of advances in gut microbiota science and where the field is headed in…

GMFH Editing Team
GMFH Editing Team

For those seeking the latest science on gut health and its applications to clinical practice, Paris was the place to be on March 11th and 12th, 2017. At the 6th GMFH World Summit, over 400 professionals from all over the world met to review the past decade of advances in gut microbiota science and where the field is headed in…

GMFH Editing Team
GMFH Editing Team

Conditions that represent some of the leading causes of mortality worldwide—including obesity, diabetes, cardiovascular disease, and cancers—are linked with observable changes in the human gut microbiota. And many other chronic conditions, like inflammatory bowel disease, asthma and allergies, rheumatoid arthritis, and even myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), have also been linked with gut microbiota dysbiosis. Scientists and the public have…

Patrice D. Cani
Professor Patrice D. Cani is researcher from the Belgian Fund for Scientific Research (FRS-FNRS), group leader in the Metabolism and Nutrition research group at the Louvain Drug Research Institute (LDRI) from the Université catholique de Louvain (UCL), Brussels, Belgium, and WELBIO (Walloon Excellence in Lifesciences and BIOtechnology) investigator. He is currently member of several international associations, he is member of the Alumni College from the Royal Belgian Academy of Sciences, and he has been elected in the board of directors of the LDRI (UCL). Patrice D. Cani has a M.Sc. in Nutrition and another M.Sc. in health Sciences, he is registered dietitian and PhD in Biomedical Sciences. His main research interests are the investigation of the role of the gut microbiota in the development of metabolic disorders, such as obesity, type 2 diabetes and low grade inflammation. More specifically, he is investigating the interactions between the gut microbiota, the host and specific biological systems such as the endocannabinoid system and the innate immune system in the context of obesity, type 2 diabetes and metabolic inflammation. Prof Cani is author and co-author of more than 110 scientific research papers published in peer-reviewed international journals, conferences and book chapters.

Conditions that represent some of the leading causes of mortality worldwide—including obesity, diabetes, cardiovascular disease, and cancers—are linked with observable changes in the human gut microbiota. And many other chronic conditions, like inflammatory bowel disease, asthma and allergies, rheumatoid arthritis, and even myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), have also been linked with gut microbiota dysbiosis. Scientists and the public have…

Patrice D. Cani
Professor Patrice D. Cani is researcher from the Belgian Fund for Scientific Research (FRS-FNRS), group leader in the Metabolism and Nutrition research group at the Louvain Drug Research Institute (LDRI) from the Université catholique de Louvain (UCL), Brussels, Belgium, and WELBIO (Walloon Excellence in Lifesciences and BIOtechnology) investigator. He is currently member of several international associations, he is member of the Alumni College from the Royal Belgian Academy of Sciences, and he has been elected in the board of directors of the LDRI (UCL). Patrice D. Cani has a M.Sc. in Nutrition and another M.Sc. in health Sciences, he is registered dietitian and PhD in Biomedical Sciences. His main research interests are the investigation of the role of the gut microbiota in the development of metabolic disorders, such as obesity, type 2 diabetes and low grade inflammation. More specifically, he is investigating the interactions between the gut microbiota, the host and specific biological systems such as the endocannabinoid system and the innate immune system in the context of obesity, type 2 diabetes and metabolic inflammation. Prof Cani is author and co-author of more than 110 scientific research papers published in peer-reviewed international journals, conferences and book chapters.
Twitter
News archive
Access from here to the chronological archive of news of this site
Access archive
Latest articles

Previous research has shown the aging process and frailty may be associated with a perturbed gut microbiome in elderly people. Indeed, gut microbes could be a major driver of age-associated inflammation in mice, and specific…

It is well-known that medications could affect the microbiome and therefore host-microbiota interactions are considered a confounding factor that can contribute to therapeutic and side effects of drug treatments. Previous research has shown that gut…

For those seeking the latest science on gut health and its applications to clinical practice, Paris was the place to be on March 11th and 12th, 2017. At the 6th GMFH World Summit, over 400…